Pharmacological revascularisation in coronary and peripheral vascular disease.

abstract：:With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. Since the first description of the CD20 mAb and its use in a single patient, it has taken more than 20 years to implement this in current t...

journal_title：Expert opinion on investigational drugs

authors： Schultze JL

更新日期：1999-12-01 00:00:00

abstract：UNLABELLED:IMPORTANCE OF THIS FIELD: Microtubule-inhibiting drugs are among the most commonly prescribed agents in the combat against cancer, though the clinical use of these drugs is limited by acquired resistance, risk of hypersensitivity reactions and intolerable toxicity. With progress in our understanding of cytos...

journal_title：Expert opinion on investigational drugs

authors： Chen SM,Meng LH,Ding J

更新日期：2010-03-01 00:00:00

abstract：INTRODUCTION:Glioblastoma is a primary brain tumor with a poor prognosis despite multimodal therapy including surgery, radiotherapy and alkylating chemotherapy. Novel therapeutic options are therefore urgently needed; however, there have been various drug failures in late-stage clinical development. The proteasome repr...

journal_title：Expert opinion on investigational drugs

authors： Roth P,Mason WP,Richardson PG,Weller M

更新日期：2020-10-01 00:00:00

abstract：:This review highlights some important advances that have taken place in cannabinoid research over the last four years. It focuses on novel ligands that are of interest either as experimental tools or as lead compounds for therapeutic agents and possible clinical applications for some of these ligands. The molecular ta...

journal_title：Expert opinion on investigational drugs

authors： Pertwee RG

更新日期：2000-07-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) incidence in the United States increases with age. Given the progressive ageing of the general population, incidence of these diseases is likely to continue to rise in the future. There is an acute need for therapeutic developments ...

journal_title：Expert opinion on investigational drugs

authors： Epling-Burnette PK,Loughran TP Jr

更新日期：2010-05-01 00:00:00

abstract：INTRODUCTION:The significant proportion of gout patients not reaching serum urate levels below 6.0 mg/dL and the debated pathogenicity of hyperuricemia (HU) itself motivate investigators to develop new drugs to decrease uricemia. AREAS COVERED:This review discusses the drugs considered to be in active development from...

journal_title：Expert opinion on investigational drugs

authors： Pascart T,Richette P

更新日期：2018-05-01 00:00:00

abstract：:The discovery of peroxisome proliferator-activated receptor gamma (PPARgamma) as the molecular target for antidiabetic thiazolidinediones has heralded a new era in the approach to understanding the pathophysiology of insulin resistance and its relationship to cardiovascular disease. However, the subsequent discovery o...

journal_title：Expert opinion on investigational drugs

authors： Pershadsingh HA

更新日期：1999-11-01 00:00:00

abstract：:Gaucher disease (GD) is an inborn error of glycosphingolipid metabolism, associated with multisystemic manifestations resulting from the lysosomal accumulation of an incompletely degraded material (glucosylceramide) within cells of monocyte/macrophage lineage. In the majority of GD patients with non-neurological invol...

journal_title：Expert opinion on investigational drugs

authors： Pastores GM,Barnett NL

更新日期：2003-02-01 00:00:00

abstract：:The beneficial effect of beta-hydroxy-beta-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in primary prevention of coronary artery disease in those with hypercholesterolaemia and in secondary prevention in those with established coronary vascular disease are now well known. A growing body of eviden...

journal_title：Expert opinion on investigational drugs

authors： Delanty N,Vaughan CJ,Sheehy N

更新日期：2001-10-01 00:00:00

abstract：INTRODUCTION:Despite recent advances, pulmonary arterial hypertension (PAH) remains a devastating disease which harbors a poor prognosis. Novel therapeutic approaches directly targeting pulmonary vascular remodeling are warranted. AREAS COVERED:This review delineates the current limitations in the management of PAH an...

journal_title：Expert opinion on investigational drugs

authors： ten Freyhaus H,Dumitrescu D,Berghausen E,Vantler M,Caglayan E,Rosenkranz S

更新日期：2012-01-01 00:00:00

abstract：:Introduction: Neuropathic pain is a chronic condition that significantly affects the quality of life of millions of people globally. Most of the pharmacologic treatments currently in use demonstrate modest efficacy and over half of all patients do not respond to medical management. Hence, there is a need for new, effi...

journal_title：Expert opinion on investigational drugs

authors： Kushnarev M,Pirvulescu IP,Candido KD,Knezevic NN

更新日期：2020-03-01 00:00:00

abstract：INTRODUCTION:The unmet need and the growing prevalence of hyperuricemia and its complications worldwide have pushed investigators to identify new agents to manage hyperuricemia. AREAS COVERED:This review discusses the drugs in preclinical and early clinical trials for hyperuricemia, their mechanisms of action and avai...

journal_title：Expert opinion on investigational drugs

authors： Shahid H,Singh JA

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:The small tyrosine kinase inhibitor Imatinib Mesylate (Gleevec) protects against diabetes, but it is not known how. AREAS COVERED:It has been suggested that islet amyloid and fibrotic deposits promote beta-cell failure and death, leading to Type-2 diabetes. As Imatinib is known to possess anti-fibrotic/am...

journal_title：Expert opinion on investigational drugs

authors： Welsh N

更新日期：2012-11-01 00:00:00

abstract：INTRODUCTION:Ewing sarcoma family tumors (ESFT) are a group of aggressive diseases, characterized histologically by small, round, blue cells and genetically by translocation involving EWS and ETS partner genes. The current treatment of localized Ewing sarcoma (ES) requires a multi-disciplinary approach, including multi...

journal_title：Expert opinion on investigational drugs

authors： Vornicova O,Bar-Sela G

更新日期：2016-06-01 00:00:00

abstract：:Inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) has an established role in the treatment of advanced non-small cell lung cancer. The first-generation EGFR inhibitors erlotinib and gefitinib have been approved for treatment in the second- and third-line setting. Second-generation ...

journal_title：Expert opinion on investigational drugs

authors： Mukherji D,Spicer J

更新日期：2009-03-01 00:00:00

abstract：BACKGROUND:Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. OBJECTIVE:To review papers published or presented at recent international meetings showing the results o...

journal_title：Expert opinion on investigational drugs

authors： Vento S,Cainelli F,Temesgen Z

更新日期：2008-11-01 00:00:00

abstract：:The discovery of new antibacterial drugs can be based either upon empirical screening methods or structure-based design. Empirical methods utilise both intact bacteria and isolated biochemical targets for high throughput screening of natural product or chemical libraries to detect inhibitor leads. Structure-based meth...

journal_title：Expert opinion on investigational drugs

authors： Chopra I

更新日期：1997-08-01 00:00:00

abstract：:Introduction: A compound that simultaneously inhibits PDE3 and PDE4 should increase airway caliber by relaxing the smooth muscle and, simultaneously, suppress airway inflammatory responses. Ensifentrine (RPL554) is considered a PDE3/4 inhibitor, although its affinity for PDE3 is 3,440 times higher than that for PDE4, ...

journal_title：Expert opinion on investigational drugs

authors： Cazzola M,Calzetta L,Rogliani P,Matera MG

更新日期：2019-10-01 00:00:00

abstract：:Telomerase is a holoenzyme responsible for the maintenance of telomeres, the protein-nucleic acid complexes at the ends of eukaryotic chromosomes that serve to maintain chromosomal stability and integrity. Telomerase activity is essential for the sustained proliferation of most immortal cells, including cancer cells. ...

journal_title：Expert opinion on investigational drugs

authors： Perry PJ,Arnold JR,Jenkins TC

更新日期：2001-12-01 00:00:00

abstract：INTRODUCTION:Studies in vitro and in vivo have identified several peptides that are potentially useful in treating systemic lupus erythematosus (SLE). The rationale for their use lies in the cost-effective production, high potency, target selectivity, low toxicity, and a peculiar mechanism of action that is mainly base...

journal_title：Expert opinion on investigational drugs

authors： Talotta R,Atzeni F,Laska MJ

更新日期：2020-08-01 00:00:00

abstract：INTRODUCTION:The purpose of this article is to highlight novel therapies that are being used in scleroderma (SSc). Therapeutic interventions in SSc generally target at least one of three ongoing biological processes characteristic of the disease: vasculopathy, autoimmunity and tissue fibrosis. Treatment decisions in SS...

journal_title：Expert opinion on investigational drugs

authors： McMahan ZH,Wigley FM

更新日期：2014-02-01 00:00:00

abstract：:Helicobacter pylori infection causes peptic ulcer disease and must be regarded as a serious infectious disease. Over the past two decades treatment of the infection has been a controversial issue. Treatment is purely empirical and based on combinations of two, three or four existing drugs. Antimicrobial resistance is ...

journal_title：Expert opinion on investigational drugs

authors： de Boer WA

更新日期：2001-08-01 00:00:00

abstract：:Background: To compare the pharmacokinetic (PK) profile, safety, and immunogenicity between golimumab and the biosimilar BAT2506 in healthy Chinese male subjects. Research design and methods: A total of 180 healthy male subjects were recruited for this randomized, double-blinded, single-dose, parallel study. They rece...

journal_title：Expert opinion on investigational drugs

authors： Wu M,Sun J,Wu D,Xu J,Wei J,Wang Z,Yu J,Li S,Zhang H,Ding Y

更新日期：2021-01-01 00:00:00

abstract：INTRODUCTION:Chagas disease treatment relies on the lengthy administration of benznidazole and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the parasite Trypanosoma cruzi, is mostly diagnosed at its chronic phase when life-threatening symptomatology manifest in approximately 30% of tho...

journal_title：Expert opinion on investigational drugs

authors： Martínez-Peinado N,Cortes-Serra N,Losada-Galvan I,Alonso-Vega C,Urbina JA,Rodríguez A,VandeBerg JL,Pinazo MJ,Gascon J,Alonso-Padilla J

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Histone deacetylases (HDACs), which target histones as well as non-histone proteins as substrates, have the potential to regulate aberrant gene expression and restore normal growth control in malignancies. OBJECTIVE:This review provides an updated summary of preclinical and clinical experience with the oral...

journal_title：Expert opinion on investigational drugs

authors： Le Tourneau C,Siu LL

更新日期：2008-08-01 00:00:00

abstract：:While oral formulations of agonists at the serotonin (5-HT) receptor subdivisions 5-HT(1B/1D)--the "triptan" class of drugs--dominate the market for migraine therapy and while still more triptans are under development, recent research efforts have also explored other pharmacological avenues, which are mostly based on ...

journal_title：Expert opinion on investigational drugs

authors： Mucke H

更新日期：2002-12-01 00:00:00

abstract：:Marfan syndrome is the most common genetic disorder of the connective tissue with an estimated prevalence of 1:10,000. The disease is characterised by manifestations in the cardiovascular, skeletal and ocular systems. The most severe manifestations are those of the cardiovascular system: mitral valve prolapse and dila...

journal_title：Expert opinion on investigational drugs

authors： Phylactou LA,Kilpatrick MW

更新日期：1999-07-01 00:00:00

abstract：:ATP-gated P2X7 receptors (P2X7) make a unique family of extracellular ATP-activated plasma membrane ion channels expressed in haematopoietic and epithelial cells. They have been extensively studied in immune cells where their activation leads to the rapid release of pro-inflammatory cytokines and the initiation of the...

journal_title：Expert opinion on investigational drugs

authors： Roger S,Pelegrin P

更新日期：2011-07-01 00:00:00

abstract：:IBC's 5(th) Annual Conference on Blood Substitutes was held on November 20-21, 1997. Approximately 100 medical researchers, academic scientists, blood substitute company speakers and representatives from major pharmaceutical companies with an interest or partner in the field attended. The papers presented focused on t...

journal_title：Expert opinion on investigational drugs

authors： Shorr RG

更新日期：1998-02-01 00:00:00

abstract：:Preclinical and clinical evidence support the effectiveness of neurotrophins in Alzheimer's disease (AD) and neurodegenerative diseases. Delivery of neurotrophins to target sites in the brain remains a major obstacle for their use in humans. Development of orally active agents that mimic the effects of nerve growth fa...

journal_title：Expert opinion on investigational drugs

authors： Glasky AJ,Glasky MS,Ritzmann RF,Rathbone MP

更新日期：1997-10-01 00:00:00